These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24132606)

  • 1. EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer.
    Xu C; Hou Z; Zhan P; Zhao W; Chang C; Zou J; Hu H; Zhang Y; Yao X; Yu L; Yan J
    Med Oncol; 2013 Dec; 30(4):713. PubMed ID: 24132606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
    Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
    PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2.
    Li Z; Xu L; Tang N; Xu Y; Ye X; Shen S; Niu X; Lu S; Chen Z
    FEBS Lett; 2014 Aug; 588(17):3000-7. PubMed ID: 24928441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.
    Shin YJ; Kim JH
    PLoS One; 2012; 7(1):e30393. PubMed ID: 22272343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
    Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
    Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
    Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
    Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
    Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
    PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma.
    Huang SD; Yuan Y; Zhuang CW; Li BL; Gong DJ; Wang SG; Zeng ZY; Cheng HZ
    Mol Cancer; 2012 Aug; 11():51. PubMed ID: 22867052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
    Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
    Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
    Lv YF; Yan GN; Meng G; Zhang X; Guo QN
    Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
    Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
    Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.